Evolent Health Stock (NYSE:EVH), Trade Ideas

Evolent Health

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

Evolent Health, Inc.  (NYSE: EVH) reported better-than-expected fourth-quarter results on Thursday.

These Analysts Revise Their Forecasts On Evolent Health After Upbeat Results

Penny Stocks

Small Cap

Intraday Update

Movers

AAOI

ACCO

AKRO

ALTI

AMSWA

ATCH

ATNI

AXTI

BKNG

CVNA

DCBO

EZFL

FOXF

GBNH

GYRE

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IBRX

IFBD

INDI

KIND

LASR

LRHC

LUNR

MELI

MODV

MRVI

OCEA

ROOT

SMCI

SMSI

SNBR

SQNS

TNDM

UPLD

VICR

VSCO

VTYX

Shares of  MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results.

Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

ACRV

ALLR

ARCB

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CMND

CRMT

DAKT

EYPT

FTCH

GNLX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GTLB

HCDI

HSCS

IBIO

JOAN

LIFW

MMSI

MYNZ

NRSN

REPL

SEEL

SOAR

SPHR

SSNT

TVTX

UCAR

VRPX

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.

Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Evolent Health Inc

EVENT HOSPITALITY & ENTMT by EVENT HOSPITALITY & ENTMT LTD.

EVT Ltd

Morgan Stanley ETF Trust Eaton Vance High Yield ETF

Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Evolent Health, revealing an average target of $44.0, a high estimate of $52.00, and a low estimate of $38.00. A 3.3% drop is evident in the current average compared to the previous average price target of $45.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1713816118_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Evolent Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Evolent Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Evolent Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Evolent Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Evolent Health analyst ratings.</a>
<h2>Unveiling the Story Behind Evolent Health</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Understanding the Numbers: Evolent Health's Finances</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Evolent Health displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 45.4%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Evolent Health's net margin excels beyond industry benchmarks, reaching -7.44%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Evolent Health's ROE excels beyond industry benchmarks, reaching -3.83%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Evolent Health's ROA excels beyond industry benchmarks, reaching -1.55%. This signifies efficient management of assets and strong financial health.
Debt Management: Evolent Health's debt-to-equity ratio surpasses industry norms, standing at 0.6. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 6 Analyst Recommendations For Evolent Health

Citigroup analyst Daniel Grosslight initiates coverage on Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy rating and announces Price Target of $40.

Initiation

Citigroup Initiates Coverage On Evolent Health with Buy Rating, Announces Price Target of $40

Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and lowers the price target from $45 to $44.

Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $44

In the preceding three months, 4 analysts have released ratings for Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Evolent Health, revealing an average target of $45.0, a high estimate of $52.00, and a low estimate of $38.00. A 1.47% drop is evident in the current average compared to the previous average price target of $45.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1710518423_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Evolent Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Evolent Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Evolent Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Evolent Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Evolent Health analyst ratings.</a>
<h2>Get to Know Evolent Health Better</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Evolent Health: Delving into Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Evolent Health's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 45.4%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -7.44%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Evolent Health's ROE stands out, surpassing industry averages. With an impressive ROE of -3.83%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Evolent Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.55% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Evolent Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.6.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 4 Analyst Ratings For Evolent Health

JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Overweight and lowers the price target from $53 to $52.

JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $52

Oppenheimer analyst Jeff Jones initiates coverage on Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Outperform rating and announces Price Target of $45.

Oppenheimer Initiates Coverage On Evolent Health with Outperform Rating, Announces Price Target of $45

Evolent Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) reported better-than-expected <a href="https://www.benzinga.com/quote/EVH/earnings">fourth-quarter results on Thursday</a>.
Evolent Health posted quarterly earnings of 23 cents per share, beating market estimates of 15 cents per share. The company&rsquo;s quarterly sales came in at $556.05 million versus market expectations of $542.39 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Seth Blackley, Chief Executive Officer, and Co-Founder of Evolent stated, &quot;We ended 2023 on a strong note, achieving all of our financial objectives for the year. Annual revenue increased over 45% while we continued to deliver strong earnings, driven by continued underlying growth as well as the successful integration of NIA. I am incredibly proud of our global team who worked so hard to collectively deliver what we promised to both shareholders and partners in 2023. Our financial position is strong as cash flow exceeded our target for the year and we significantly improved our cash and balance sheet flexibility.&quot;
Evolent Health shares gained 11.5% to trade at $33.20 on Friday.
These analysts made changes to their price targets on Evolent Health after the company reported&nbsp;results for the recent quarter.
<ul>
<li>Canaccord Genuity cut the price target on Evolent Health from $47 to $45. Canaccord Genuity analyst Richard Close maintained a Buy rating.</li>
<li>JMP Securities raised the price target on Evolent Health from $37 to $38. JMP Securities analyst Constantine Davides maintained a Market Outperform rating.</li>
</ul>
&nbsp;
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37254407/jim-cramer-unity-software-had-problems-but-zscaler-is-a-good-one-to-buy"> Jim Cramer: Unity Software &#39;Had Problems,&#39; But Zscaler Is A &#39;Good One&#39; To Buy</a>

Shares of MercadoLibre, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meli#NASDAQ">MELI</a>) fell sharply during Friday&rsquo;s session after the company reported <a href="https://www.benzinga.com/news/earnings/24/02/37274889/mercadolibre-reports-mixed-q4-results-earnings-miss-revenues-beat">fourth-quarter financial results.</a>
MercadoLibre reported quarterly earnings of $3.25 per share, unchanged from the same period last year. The company reported quarterly sales of $4.26 billion, beating the analyst consensus estimate of $4.12 billion.
MercadoLibre shares dipped 9.6% to $1,643.30 on Friday.
Here are some other stocks moving in today&#39;s mid-day session.
Gainers
<ul>
<li>AXT, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axti#NASDAQ">AXTI</a>) shares surged 74.4% to $3.9750 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Maravai LifeSciences Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvi#NASDAQ">MRVI</a>) shares jumped 60.8% to $8.22 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>AtlasClear Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/atch#NYSE">ATCH</a>) rose 48% to $1.6899.</li>
<li>EZFill Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ezfl#NASDAQ">EZFL</a>) gained 44.6% to $ 1.8088.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) jumped 42.3% to $0.7819.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) gained 36.2% to $21.79.</li>
<li>Carvana Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvna#NYSE">CVNA</a>) rose 31.2% to $68.77 after the company reported fourth-quarter financial results.</li>
<li>Sleep Number Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snbr#NASDAQ">SNBR</a>) gained 30.5% to $14.42 after the company reported better-than-expected fourth-quarter financial results. Also, Wedbush maintained a Neutral rating on the stock and raised its price target from $12 to $13.5.</li>
<li>ATN International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atni#NASDAQ">ATNI</a>) rose 26% to $ 35.72.</li>
<li>Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) gained 26% to $16.85 after the company reported better-than-expected fourth-quarter financial results. Following earnings, Cantor Fitzgerald upgraded the stock from Neutral to Overweight and raised its price target from $9 to $13.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) gained 25.7% to $3.72.</li>
<li>Vroom, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrm#NASDAQ">VRM</a>) jumped 25.5% to $ 10.50. Vroom is expected to release fourth quarter earnings on March 13, 2024.</li>
<li>ATN International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atni#NASDAQ">ATNI</a>) rose 25.4% to $35.61.</li>
<li>Intuitive Machines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lunr#NASDAQ">LUNR</a>) gained 22.4% to $10.14 after the company&#39;s Odysseus spacecraft landed on the Moon.</li>
<li>Block, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sq#NYSE">SQ</a>) climbed 19.4% to $81.20 after the company reported better-than-expected fourth-quarter sales results and issued guidance.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) gained 18.3% to $6.82.</li>
<li>Universal Insurance Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uve#NYSE">UVE</a>) gained 18.2% to $20.37 following upbeat results.</li>
<li>Docebo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dcbo#NASDAQ">DCBO</a>) gained 17.7% to $53.99 following upbeat quarterly results.</li>
<li>Universal Insurance Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uve#NYSE">UVE</a>) shares rose 17.2% to $20.20 following strong quarterly results.</li>
<li>Nextdoor Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kind#NASDAQ">KIND</a>) gained 16.9% to $2.0101 after the company reported preliminary fourth-quarter financial results and announced Nirav Tolia will return to the company as CEO.</li>
<li>Evolent Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) gained 12.6% to $33.54 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tndm#NASDAQ">TNDM</a>) climbed 12.1% to $28.02 amid volatility after the company reported fourth-quarter financial results.</li>
<li>American Software, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amswa#NASDAQ">AMSWA</a>) gained 11.6% to $11.49 following strong quarterly results.</li>
<li>Akero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>) surged 11% to $26.86.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) climbed 10.6% to $6.39.</li>
<li>LegalZoom.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lz#NASDAQ">LZ</a>) gained 10.5% to $10.87 after the company reported better-than-expected fourth-quarter financial results and issued FY24 revenue guidance. </li>
<li>Vir Biotechnology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vir#NASDAQ">VIR</a>) rose 10.3% to $11.36 following strong sales results.</li>
<li>Comfort Systems USA, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fix#NYSE">FIX</a>) rose 10.2% to $273.10 after the company reported better-than-expected fourth-quarter results.</li>
<li>Hyatt Hotels Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/h#NYSE">H</a>) climbed 8.9% to $147.66 after the company reported better-than-expected fourth-quarter sales results and issued guidance.</li>
<li>RB Global, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rba#NYSE">RBA</a>) rose 8.2% to $73.98 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued guidance.</li>
<li>Victoria&#39;s Secret &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vsco#NYSE">VSCO</a>) gained 5% to $29.75.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sequans Communications S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sqns#NYSE">SQNS</a>) fell 65% to $0.8925 after Renesas announced that it has terminated the previously announced MOU for a proposed acquisition of Sequans.</li>
<li>Smith Micro Software, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smsi#NASDAQ">SMSI</a>) shares fell 41.5% to $0.4781 after posting weak quarterly sales.</li>
<li>ModivCare Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/modv#NASDAQ">MODV</a>) fell 39.9% to $26.39 after the company issued weak sales forecast for the first quarter.</li>
<li>Greenbrook TMS Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gbnh#NASDAQ">GBNH</a>) dipped 37% to $0.1285 after announcing delisting from the Nasdaq.</li>
<li>Upland Software, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upld#NASDAQ">UPLD</a>) tumbled 34.5% to $2.8890 after the company reported worse-than-expected fourth-quarter adjusted EPS results and issued FY24 revenue guidance below estimates.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aaoi#NASDAQ">AAOI</a>) shares fell 31.2% to $14.00 after reporting fourth-quarter results.</li>
<li>MicroCloud Hologram Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holo#NASDAQ">HOLO</a>) fell 29.3% to $7.79.</li>
<li>Fox Factory Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/foxf#NASDAQ">FOXF</a>) tumbled 27% to $47.38 after the company reported mixed fourth-quarter financial results and issued FY24 EPS and revenue guidance below estimates.</li>
<li>ImmunityBio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ibrx#NASDAQ">IBRX</a>) fell 25% to $3.9299.</li>
<li>Vicor Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vicr#NASDAQ">VICR</a>) fell 21.2% to $36.92 after the company reported worse-than-expected quarterly financial results.</li>
<li>Gray Television, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gtn#NYSE">GTN</a>) fell 21.2% to $6.26 after the company reported a year-over-year decrease in fourth-quarter financial results and issued first-quarter revenue guidance below estimates.</li>
<li>La Rosa Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lrhc#NASDAQ">LRHC</a>) shares dipped 19.2% to $2.2150 after jumping around 96% on Thursday. La Rosa Holdings disclosed that it has acquired a 100% interest in the La Rosa Realty Winter Garden franchise in Florida.</li>
<li>The E.W. Scripps Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssp#NASDAQ">SSP</a>) fell 15% to $4.58 following weak quarterly earnings.</li>
<li>AlTi Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alti#NASDAQ">ALTI</a>) dipped 14.6% to $6.02.</li>
<li>indie Semiconductor, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/indi#NASDAQ">INDI</a>) shares fell 14.2% to $5.91 following weak quarterly sales.</li>
<li>nLIGHT, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lasr#NASDAQ">LASR</a>) fell 13.6% to $11.93 following fourth-quarter results.</li>
<li>ACCO Brands Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/acco#NYSE">ACCO</a>) declined 12.2% to $5.64 after the company reported fourth-quarter financial results and issued weak FY24 guidance.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) fell 12% to $858.42 after the company announced a private offering of convertible senior notes.</li>
<li>Booking Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bkng#NASDAQ">BKNG</a>) shares fell 9.7% to $3,522.25 after the company reported fourth-quarter financial results.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wbd#NASDAQ">WBD</a>) fell 9.3% to $8.68 after the company reported fourth-quarter financial results below estimates.</li>
<li>Penumbra, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pen#NYSE">PEN</a>) fell 8% to $241.77 after the company reported mixed fourth-quarter financial results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/02/37283655/intuit-to-rally-around-14-here-are-10-top-analyst-forecasts-for-friday"> Intuit To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday </a>

Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.5, along with a high estimate of $45.00 and a low estimate of $37.00. A decline of 5.09% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1708711283_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Evolent Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Evolent Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Evolent Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Evolent Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Evolent Health analyst ratings.</a>
<h2>Unveiling the Story Behind Evolent Health</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. The company's two reportable segments: EHS and Clinical Solutions. The Company's EHS segment provides an integrated administrative and clinical platform for health plan administration and value-based business infrastructure and clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for specialty care management in oncology and cardiology and increasingly the musculoskeletal markets and holistic total cost of care improvement. It generates a majority of its revenue from Clinical Solutions segment.
<h3>Evolent Health: A Financial Overview</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Evolent Health displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 44.93%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Evolent Health's net margin excels beyond industry benchmarks, reaching -6.5%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Evolent Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.03% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.25%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.6.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For Evolent Health

JMP Securities analyst Constantine Davides maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Market Outperform and raises the price target from $37 to $38.

JMP Securities Maintains Market Outperform on Evolent Health, Raises Price Target to $38

Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and lowers the price target from $47 to $45.

Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $45

WIIM

Evolent Health shares are trading higher after the company reported better-than-expected Q4 financial results.

Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.15 by 53.33 percent. This is a 130 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $556.05 million which beat the analyst consensus estimate of $542.39 million by 2.52 percent. This is a 45.40 percent increase over sales of $382.43 million the same period last year.

Evolent Health Q4 EPS $0.23 Beats $0.15 Estimate, Sales $556.05M Beat $542.39M Estimate

Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) reported quarterly sales of $556.05 million which beat the analyst consensus estimate of $542.40 million by 2.52 percent. This is a 45.40 percent increase over sales of $382.43 million the same period last year.

Earnings Beats

Evolent Health Q4 Sales $556.05M Beat $542.40M Estimate

<h3>Gainers</h3>
<ul>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares rose 114.3% to $0.97 during Thursday's after-market session. The market value of their outstanding shares is at $29.0 million. </li>
<li>Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) shares rose 17.41% to $6.0. The market value of their outstanding shares is at $793.1 million. As per the news, the Q4 earnings report came out today. </li>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) stock rose 11.89% to $0.5. The market value of their outstanding shares is at $23.9 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares increased by 10.11% to $0.98. The company's market cap stands at $2.3 million. </li>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) stock moved upwards by 8.22% to $0.46. The company's market cap stands at $120.8 million. </li>
<li>Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) shares moved upwards by 7.49% to $32.0. The market value of their outstanding shares is at $3.6 billion. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) stock fell 15.1% to $6.96 during Thursday's after-market session. The company's market cap stands at $180.2 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) shares fell 10.54% to $235.0. The company's market cap stands at $9.0 billion. As per the news, the Q4 earnings report came out today. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares declined by 8.78% to $0.29. The company's market cap stands at $2.7 million. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) stock declined by 8.17% to $8.1. The company's market cap stands at $1.8 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Acutus Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) stock fell 7.46% to $0.21. The company's market cap stands at $6.0 million. </li>
<li>Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) shares decreased by 6.68% to $183.99. The market value of their outstanding shares is at $12.8 billion. As per the news, the Q4 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AFIB

ARDX

BSGM

OTLK

PODD

TBIO

VRAX

12 Health Care Stocks Moving In Thursday's After-Market Session

Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-22. Here's what investors need to know before the announcement.
Analysts estimate that Evolent Health will report an earnings per share (EPS) of $0.15. 
Evolent Health bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.23, which was followed by a 13.54% increase in the share price the next day.
Here's a look at Evolent Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.07</td>
<td>0.09</td>
<td>0.20</td>
<td>0.16</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.30</td>
<td>0.14</td>
<td>0.21</td>
<td>0.10</td>
</tr>
<tr>
<td>Price Change %</td>
<td>13.54%</td>
<td>-5.1%</td>
<td>-4.69%</td>
<td>10.58%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1708527658_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Evolent Health were trading at $30.74 as of February 20. Over the last 52-week period, shares are down 13.92%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/EVH/earnings">To track all earnings releases for Evolent Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evolent Health's Earnings: A Preview

Within the last quarter, Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) has observed the following analyst ratings: 
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the last 3 months, 4 analysts have offered 12-month price targets for Evolent Health. The company has an average price target of $39.75 with a high of $46.00 and a low of $34.00. 
Below is a summary of how these 4 analysts rated Evolent Health over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1701867637_0.png" alt="price target chart" />
This current average represents a 0.62% decrease from the previous average price target of $40.00. 
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Evolent Health analyst ratings.</a>
<h1>How Are Analyst Ratings Determined?</h1>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations for Evolent Health's Future

JMP Securities analyst Constantine Davides initiates coverage on Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Market Outperform rating and announces Price Target of $37.

JMP Securities Initiates Coverage On Evolent Health with Market Outperform Rating, Announces Price Target of $37

Interest on the notes is payable semiannually in arrears on&nbsp;June 1&nbsp;and&nbsp;December 1&nbsp;of each year, beginning on&nbsp;June 1, 2024, at a rate equal to&nbsp;3.50%&nbsp;per annum. The notes will mature on&nbsp;December 1, 2029&nbsp;unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.

Evolent Health Prices $350M 3.50% Convertible Senior Notes Due 2029 To Pay Down Senior Term Loan

Shares of Daktronics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dakt#NASDAQ">DAKT</a>) moved lower during Tuesday&rsquo;s session following <a href="https://www.benzinga.com/quote/DAKT/earnings">weak quarterly results</a>.
Daktronics posted quarterly earnings of 5 cents per share, missing market estimates of 13 cents per share. The company&rsquo;s quarterly sales came in at $199.37 million versus expectations of $213.70 million, according to <a href="http://pro.benzinga.com/">Benzinga Pro</a>.
Daktronics shares declined 10.7% to $9.15 on Tuesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Meiwu Technology Company Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wnw#NASDAQ">WNW</a>) shares climbed 80.6% to $0.13.</li>
<li>Volato Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/soar#NYSE">SOAR</a>) shares gained 72% to $15.13.</li>
<li>Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmnd#NASDAQ">CMND</a>) jumped 62.6% to $6.23 after the company announced results in its cocaine addiction treatment.</li>
<li>Allarity Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allr#NASDAQ">ALLR</a>) climbed 46.9% to $0.8946 after the company announced initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of stenoparib in women with advanced ovarian cancer.</li>
<li>Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) gained 30% to $0.0361 after gaining 29% on Monday. NXU named Sarah Wyant as interim CFO, succeeding Apoorv Dwivedi.</li>
<li>XBP Europe Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xbp#NASDAQ">XBP</a>) surged 24.7% to $47.40.</li>
<li>Travere Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tvtx#NASDAQ">TVTX</a>) gained 24% to $7.80. Travere completed&nbsp;successful pre-NDA meeting for FILSPARI in IgAN. Citigroup upgraded Travere Therapeutics from Neutral to Buy and raised the price target from $7 to $10.</li>
<li>Harbor Custom Development, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hcdi#NASDAQ">HCDI</a>) climbed 19.4% to $1.29.</li>
<li>Mercurity Fintech Holding Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mfh#NASDAQ">MFH</a>) surged 17% to $1.3806. Mercurity Fintech announced a $6 million private placement financing.</li>
<li>Heart Test Laboratories, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hscs#NASDAQ">HSCS</a>) jumped 15.7% to $0.2179. HeartSciences received FDA confirmation to change clearance pathway for MyoVista wavECG device and associated AI-ECG algorithm to a 510(k) submission from a De Novo process.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) gained 15.5% to $18.56.</li>
<li>Acrivon Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acrv#NASDAQ">ACRV</a>) climbed 13.2% to $5.93.</li>
<li>MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) gained 12% to $3.7600.</li>
<li>EyePoint Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eypt#NASDAQ">EYPT</a>) rose 8.3% to $19.86.</li>
<li>GitLab Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gtlb#NASDAQ">GTLB</a>) rose 6.8% to $56.55 after the company posted better-than-expected results for its third quarter and issued a strong forecast for FY24.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Replimune Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/repl#NASDAQ">REPL</a>) shares fell 48.1% to $6.39 after the company announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for the treatment of locally advanced or metastatic CSCC and provided initial data for all patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial.</li>
<li>iBio, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ibio#NYSE">IBIO</a>) dipped 42.1% to $1.5625 after the company announced pricing of a $4.5 million public offering.</li>
<li>Designer Brands Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dbi#NYSE">DBI</a>) fell 31.2% to $8.81 after the company reported worse-than-expected third-quarter financial results and lowered FY23 adjusted EPS guidance.</li>
<li>U Power Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ucar#NASDAQ">UCAR</a>) declined 26.9% to $0.4999. U Power recently announced pricing of its registered follow-on offering.</li>
<li>SilverSun Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssnt#NASDAQ">SSNT</a>) shares fell 24.7% to $9.40 after jumping 240% on Monday. SilverSun Technologies announced Jacobs Private Equity II and minority co-investors will invest $1 billion in the company.</li>
<li>NeuroSense Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrsn#NASDAQ">NRSN</a>) fell 24.2% to $1.1293. NeuroSense said it met its primary safety and tolerability &amp; secondary clinical efficacy endpoints in its Phase 2b PARADIGM trial of PrimeC in ALS.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) shares fell 23.7% to $0.6799 after the company reported third-quarter earnings.</li>
<li>Mainz Biomed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>) dipped 23% to $1.2250. Mainz Biomed reported topline results from U.S. eAArly DETECT study evaluating novel mRNA biomarkers.</li>
<li>GRI Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gri#NASDAQ">GRI</a>) shares fell 19.1% to $0.5968. GRI Bio commenced patient enrollment in Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of idiopathic pulmonary fibrosis.</li>
<li>Seelos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/seel#NASDAQ">SEEL</a>) declined 18.4% to $1.60.</li>
<li>America&#39;s Car-Mart, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crmt#NASDAQ">CRMT</a>) fell 18% to $66.31 after the company reported second-quarter financial results.</li>
<li>Alterity Therapeutics Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athe#NASDAQ">ATHE</a>) dipped 14.8% to $3.58. Alterity Therapeutics will host webcast to discuss ATH434 efficacy data in primates and recent clinical progress on Tuesday, Dec. 5 in the US.</li>
<li>Sphere Entertainment Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sphr#NYSE">SPHR</a>) declined 13.5% to $29.07. Sphere Entertainment announced a private offering of $225 million of convertible senior notes.</li>
<li>Genelux Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnlx#NASDAQ">GNLX</a>) fell 12.8% to $11.85.</li>
<li>Evolent Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) fell 10.8% to $26.15 after the company announced a proposed offering of $350M of convertible senior notes due 2029.</li>
<li>Worthington Steel, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ws#NYSE">WS</a>) declined 9.6% to $21.82.</li>
<li>Farfetch Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftch#NASDAQ">FTCH</a>) fell 9.6% to $1.1650.</li>
<li>ArcBest Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arcb#NASDAQ">ARCB</a>) dipped 9.4% to $113.14.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrpx#NASDAQ">VRPX</a>) fell 8.5% to $0.4150 after surging 12% on Monday. Virpax Pharmaceuticals recently appointed Gerald Bruce as CEO and Eric Floyd as Chairman.</li>
<li>Merit Medical Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mmsi#NASDAQ">MMSI</a>) shares fell 8.3% to $67.79 after the company reported a proposed private placement of $550 million of convertible senior notes.</li>
<li>GameStop Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gme#NYSE">GME</a>) fell 8.2% to $15.60.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/23/12/36093122/ethereum-falls-but-remains-above-this-key-level-ftx-token-gnosis-among-top-losers"> Ethereum Falls But Remains Above This Key Level; FTX Token, Gnosis Among Top Losers</a>

Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

RBC Capital analyst Sean Dodge maintained a Buy rating on Evolent Health (EVH – Research Report) today and set a price target of $42.00. The compan...

Evolent Health (EVH) Receives a Buy from RBC Capital

BTIG analyst David Larsen has maintained their bullish stance on EVH stock, giving a Buy rating today. David Larsen has given his Buy rating due to...

Evolent Health Outperforms with Strong Q4 Results and Promising Growth Outlook: A Buy Rating from Analyst David Larsen

Evolent Health files to sell Class A common stock, no amount given

In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on Evolent Health (EVH – Research Report), with a price ...

Truist Financial Remains a Hold on Evolent Health (EVH)

Truist Financial analyst Jailendra Singh assigned a Hold rating to the stock today. The company's shares closed yesterday at $34.72. According to T...

Evolent Health (EVH) Gets a Hold from Truist Financial

Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bausch Health Companies (BHC – Research Report), Blueprint Medici...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch Health Companies (BHC), Blueprint Medicines (BPMC) and Evolent Health (EVH)

Analysts fell to the sidelines weighing in on Bausch Health Companies (BHC – Research Report), Walgreens Boots Alliance (WBA – Research Report) and...

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Walgreens Boots Alliance (WBA) and Evolent Health (EVH)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evolent Health (EVH – Research Report), Nurix Therap...

Analysts' Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB – Research Report), Evolent Health (E...